Prolynx

About Prolynx

Prolynx is a biotechnology company focused on developing ultra-long-acting medicines for obesity and related metabolic diseases, with a portfolio designed for once-monthly and once-quarterly dosing using proven half-life extension technology for consistent, long-term treatment with improved tolerability and optimized pharmacokinetics.

Products & Services

Ultra-Long-Acting Medicines:A portfolio of extended-duration therapeutic candidates for obesity and related metabolic diseases, designed for once-monthly and once-quarterly dosing.

Specialties

Ultra-Long-Acting Medicines Half-Life Extension Technology Obesity Treatment Metabolic Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 70000000 MR: - FA: $70 million FAN: 70000000	D: 2025-12-11 FD: 2025-12-11	3 investors

Series A Latest

2025-12-11

$70.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Chris Boulton

CEO

Recent News

Prolynx Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised